Addressing the Unmet Needs in Pediatric Mild-Moderate Atopic Dermatitis: The Role of PDE-4 Inhibitors

 

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is common in young children and can affect the quality of life of both patients and caregivers. Topical corticosteroids are widely used, but concerns about using them for a long time or over and over, especially in children, mean there is a need for effective steroid-free options.

This activity looks at PDE4 inhibitors as a treatment option for mild-to-moderate AD in children. It centres on the INTEGUMENT-PED phase 3 trial, which tested once-daily roflumilast cream 0.05% against a vehicle cream in 652 children aged 2 to 5 years. After 4 weeks, children treated with roflumilast did significantly better than the vehicle group on:

  • overall disease clearance
  • reduction in eczema severity
  • itch, with improvement seen within 24 hours of the first application

The cream was well tolerated, with few side effects. Because very little of the drug is absorbed into the body, it may be safer than PDE4 inhibitors taken by mouth. The activity also discusses how PDE4 inhibitors can be used in a targeted way and combined with other treatments. This includes their role in cutting down steroid use and keeping AD under control over the long term.

Target Audience

Healthcare Professionals

Learning Objectives

  • Enhance healthcare professionals' knowledge on PDE4 inhibitor based therapeutic options for treatment of mild-to-moderate atopic dermatitis in children.
  • Enhance healthcare professionals' knowledge on the therapeutic potentials of PDE4 inhibitors by precise pharmacological adoption and combination therapy for treating atopic dermatitis.

Activity Disclosures

This CME activity was sponsored by an educational grant from Arcutis Biotherapeutics Inc. All planners involved in the development of this activity declared no relevant financial relationships with ineligible companies.

This activity underwent peer review in line with the standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
12/01/2025
Course expires: 
11/30/2028
Cost:
$0.00
Rating: 
0

Article Authors: Lawrence F. Eichenfield, Rocco Serrao, Vimal H. Prajapati, John C. Browning, Lisa Swanson, Tracy Funk, Mercedes E. Gonzalez, Adelaide A. Hebert, Mark Lee, Mark Boguniewicz, Eric L. Simpson, Melissa S. Seal, David Krupa, Diane Hanna, Scott Snyder, Patrick Burnett, David H. Chu, Erin Almaraz, Robert C. Higham, David R. Berk

This activity underwent peer review in line with the standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within 1 hour. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, up to 3 attempts and a score of 80% or better is needed to pass the post test and claim CC credit. [ACGME competency/CC category: Medical Knowledge].

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Price

Cost:
$0.00
Please login or register to take this course.